CD4 T cell-derived IL-2 counteracts rapamycin-mediated suppression of CD8 T cell effector differentiation in acute GvHD
Ontology highlight
ABSTRACT: Graft-versus-host disease (GvHD) remains a major limitation in the success of allogeneic hematopoietic stem cell transplantation. Rapamycin, an mTOR inhibitor, is used to control alloreactive T cell responses, but its effects on differentiation of donor T cell subsets in vivo are not fully understood. We previously identified two major subsets of alloreactive CD8⁺ T cells that arise during acute GvHD, including TCF1⁺ progenitor-like and Tim-3⁺ terminal effector populations. In this study, we examined how rapamycin influences the activation, circulation, and differentiation states of donor CD8⁺ T cells in murine acute GvHD models, both with and without donor CD4⁺ T cell help. Single-cell RNA sequencing was performed on donor-derived T cells collected from multiple experimental conditions to define the transcriptional programs associated with rapamycin treatment, CD4⁺ T cell involvement, and effector commitment. This dataset enables further investigation of the cellular mechanisms regulating T cell differentiation during GvHD under mTOR inhibition.
ORGANISM(S): Mus musculus
PROVIDER: GSE313537 | GEO | 2026/06/01
REPOSITORIES: GEO
ACCESS DATA